1rgb

From Proteopedia

Phospholipase A2 from Vipera ammodytes meridionalis

Structural highlights

1rgb is a 4 chain structure with sequence from Vipera ammodytes meridionalis. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:	X-ray diffraction, Resolution 3.3Å
Ligands:
Resources:	FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

PA2B_VIPAE Heterodimer: postsynaptic neurotoxin. Monomer: snake venom phospholipase A2 (PLA2) that shows hemolytic activity and inhibition of platelet aggregation. The hemolytic activity occurs only in presence of fatty acids (unsaturated fatty acids facilitate induce a strong hemolytic activity, whereas saturated fatty acids induce a slight activity). The inhibition of platelet aggregation is almost maximal when aggregation is induced by collagen, and arachidonic acid, whereas it is only of 30% when the aggregation is induced by ADP. PLA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides.

Evolutionary Conservation

Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.

Publication Abstract from PubMed

The inhibition of phospholipase A(2)s (PLA(2)s) is of pharmacological and therapeutic interest because these enzymes are involved in several inflammatory diseases. Elaidoylamide is a powerful inhibitor of a neurotoxic PLA(2) from the Vipera ammodytes meridionalis venom. The X-ray structure of the enzyme-inhibitor complex reveals a new mode of Asp49 PLA(2) inhibition by a fatty acid hydrocarbon chain. The structure contains two identical homodimers in the asymmetric unit. In each dimer one subunit is rotated by 180 degrees with respect to the other and the two molecules are oriented head-to-tail. One molecule of elaidoylamide is bound simultaneously to the substrate binding sites of two associated neurotoxic phospholipase A(2) molecules. The inhibitor binds symmetrically to the hydrophobic channels of the two monomers. The structure can be used to design anti-inflammatory drugs.

Asp49 phospholipase A(2)-elaidoylamide complex: a new mode of inhibition.,Georgieva DN, Rypniewski W, Gabdoulkhakov A, Genov N, Betzel C Biochem Biophys Res Commun. 2004 Jul 9;319(4):1314-21. PMID:15194511^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

↑ Georgieva DN, Rypniewski W, Gabdoulkhakov A, Genov N, Betzel C. Asp49 phospholipase A(2)-elaidoylamide complex: a new mode of inhibition. Biochem Biophys Res Commun. 2004 Jul 9;319(4):1314-21. PMID:15194511 doi:10.1016/j.bbrc.2004.05.106